Jim Middelburg

6PUBLICATIONS
47CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Supramolecular chemistryMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 03, 2025
Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery.

Amanda X Y Chen, Kah Min Yap, Joelle S Kim

|Apr 09, 2025
Site-directed multivalent conjugation of antibodies to ubiquitinated payloads.

Angela F El Hebieshy, Zacharias Wijfjes, Camille M Le Gall

|Jan 12, 2025
Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy.

Jim Middelburg, Gaby Schaap, Marjolein Sluijter

|Jan 03, 2024
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.

Jim Middelburg, Marjolein Sluijter, Gaby Schaap

|Apr 14, 2022
A Single-Domain TCR-like Antibody Selective for the Qa-1<sup>b</sup>/Qdm Peptide Complex Enhances Tumoricidal Activity of NK Cells via Blocking the NKG2A Immune Checkpoint.

Soroush Ghaffari, Katherine Upchurch-Ange, Susanne Gimlin

|Jan 20, 2021
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors.

Jim Middelburg, Kristel Kemper, Patrick Engelberts

Pageof 1